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cis-Diammine-dichloroplatinum (cisplatin, CDDP) is an estab-
lished anticancer drug with activity in a variety of solid tumour
types, including head and neck cancer (HNC), ovarian cancer and
non-small-cell lung carcinoma (NSCLC). Its major disadvantage,
however, is a relapse in most tumours after an initial response
(Scanlon et al, 1991). CDDP is generally considered to exert its
cytotoxic effect by binding to DNA, resulting in a number of
different adducts (Sundquist et al, 1990). A tentative relationship
between platinum–DNA adduct (Pt–DNA adduct) levels and anti-
tumour response in cultured cells (Terheggen et al, 1990) and in
patients has been postulated (Parker et al, 1991).
2¢,2¢-Difluorodeoxycytidine (gemcitabine, dFdC) is a deoxy-
cytidine analogue (Hertel et al, 1988) with clinical activity against
several solid tumours, such as ovarian cancer, NSCLC, HNC and
pancreatic cancer (Van Moorsel et al, 1997). After entering the cell,
dFdC is phosphorylated to its triphosphate (dFdCTP) which can be
incorporated into DNA, followed by one more deoxynucleotide, after
which DNA polymerization stops (Huang et al, 1991), which prob-
ably determines its cytotoxic effect. Besides this effect, dFdC is also
capable of inhibiting ribonucleotide reductase (RR) (Heinemann et
al, 1988), an enzyme with a key role in DNA repair mechanisms.
Because of the mechanisms of action and different side-effects,
CDDP being nephrotoxic and dFdC being myelotoxic, combination
of these drugs has been investigated. In in vitro and in vivo studies
a synergistic effect of both drugs was found in both CDDP-resistant
and non-resistant tumours and tumour cell lines (Braakhuis et al,
1995; Bergman et al, 1996). Several possible mechanisms could be
responsible for this interaction; CDDP might influence dFdC
metabolism at its activation site or at the DNA level, while dFdC
might interact with the accumulation of CDDP, the extent or nature
of DNA platination, or the process of DNA repair. Previously, we
observed that the accumulation of dFdCTP in a human ovarian
cancer cell line (A2780) was not influenced by CDDP, but CDDP
did cause a decrease of 40% of dFdCTP pools in the A2780 CDDP-
resistant variant, ADDP. DNA strand break (DSB) formation in
A2780 cells was lower at simultaneous incubation of both drugs
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Summary 2¢,2¢-Difluorodeoxycytidine (gemcitabine, dFdC) and cis-diammine-dichloroplatinum (cisplatin, CDDP) are active agents against
ovarian cancer and non-small-cell lung cancer (NSCLC). CDDP acts by formation of platinum (Pt)–DNA adducts; dFdC by dFdCTP
incorporation into DNA, subsequently leading to inhibition of exonuclease and DNA repair. Previously, synergism between both compounds
was found in several human and murine cancer cell lines when cells were treated with these drugs in a constant ratio. In the present study we
used different combinations of both drugs (one drug at its IC25 and the other in a concentration range) in the human ovarian cancer cell line
A2780, its CDDP-resistant variant ADDP, its dFdC-resistant variant AG6000 and two NSCLC cell lines, H322 (human) and Lewis lung (LL)
(murine). Cells were exposed for 4, 24 and 72 h with a total culture time of 96 h, and possible synergism was evaluated by median drug effect
analysis by calculating a combination index (CI; CI < 1 indicates synergism). With CDDP at its IC25, the average CIs calculated at the IC50, IC75
IC90 and IC95 after 4, 24 and 72 h of exposure were < 1 for all cell lines, indicating synergism, except for the CI after 4 h exposure in the LL cell
line which showed an additive effect. With dFdC at its IC25, the CIs for the combination with CDDP after 24 h were < 1 in all cell lines, except
for the Cls after 4 h exposure in the LL and H322 cell lines which showed an additive effect. At 72 h exposure all Cls were < 1. CDDP did not
significantly affect dFdCTP accumulation in all cell lines. CDDP increased dFdC incorporation into both DNA and RNA of the A2780 cell lines
33- and 79-fold (P < 0.01) respectively, and tended to increase the dFdC incorporation into RNA in all cell lines. In the AG6000 and LL cell
lines, CDDP and dFdC induced > 25% more DNA strand breaks (DSB) than each drug alone; however, in the other cell lines no effect, or even
a decrease in DSB, was observed. dFdC increased the cellular Pt accumulation after 24 h incubation only in the ADDP cell line. However,
dFdC did enhance the Pt–DNA adduct formation in the A2780, AG6000, ADDP and LL cell lines (1.6-, 1.4-, 2.9- and 1.6-fold respectively).
This increase in Pt–DNA adduct formation seems to be related to the incorporation of dFdC into DNA (r = 0.91). No increase in DNA
platination was found in the H322 cell line. dFdC only increased Pt–DNA adduct retention in the A2780 and LL cell lines, but decreased the
Pt–DNA adduct retention in the AG6000 cell line. In conclusion, the synergism between dFdC and CDDP appears to be mainly due to an
increase in Pt–DNA adduct formation possibly related to changes in DNA due to dFdC incorporation into DNA.
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fore concluded that the synergistic interaction is possibly caused by
an effect of dFdC on the cellular metabolism of CDDP. dFdC may
inhibit DNA repair, leading to a decreased rate of repair of Pt–DNA
adducts by the cancer cell.
The purpose of the present investigation was to elucidate
possible mechanisms of synergism between dFdC and CDDP.
Emphasis was on ovarian and NSCLC cells, since combinations of
both compounds have led to increased response rates of up to 54%
in NSCLC and 71% in ovarian cancer clinical studies (Steward et
al, 1996; Abratt et al, 1997; Crino et al, 1997; Van Moorsel et al,
1997; Krakowski et al, 1998; Nogue et al, 1998).
We compared the effect of CDDP on accumulation of dFdCTP,
dFdC incorporation into DNA and RNA, and the extent of DNA-
DSB caused by the combination, with the effects of dFdC on the
accumulation of CDDP and formation and retention of Pt–DNA
adducts.
MATERIALS AND METHODS
Drugs and chemicals
dFdC (Gemcitabine) and [5-3H]-dFdC (16.7 Ci mmol–1) were a kind
gift of Eli Lilly Inc. (Indianapolis, IN, USA) and were solubilized
with phosphate-buffered saline (PBS) to a concentration of 10 mM.
CDDP (cisplatin) was obtained from Bristol-Myers Squibb
(Woerden, The Netherlands) and solubilized with PBS to a concen-
tration of 3 mM. Final dilutions of both drugs were made in culture
medium. All other chemicals were of analytical grade and commer-
cially available.
Cell culture
The experiments were performed with five different cell lines, with
two major histological subtypes. For human ovarian cancer, A2780
was the parental cell line (Lu et al, 1988; Ruiz van Haperen et al,
1994a), ADDP, the variant with induced resistance to CDDP (Lu
et al, 1988), and AG6000, the variant with induced resistance to
gemcitabine (Ruiz van Haperen et al, 1994a). The ADDP cell line
was included as a model for CDDP resistance due to both a
decreased accumulation and Pt-DNA adduct formation. The
AG6000 cell line was included as a negative control since gemc-
itabine is not activated in this cell line. For NSCLC we used the
human H322 cell line (subtype BAC, NCI), and the murine LL
tumour cell line (kindly provided by Dr Lelieveld). The murine cell
line was included because this line is relatively resistant to CDDP
and gemcitabine, both in-vitro and in-vivo. Therefore, the cell line
was also used in simultaneously ongoing animal experiments
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Table 1 IC50s for all cell lines after 4-, 24- and 72-h exposure to each drug alone
Cell line CDDP (mM) dFdC (nM)
4h 2 4h 7 2h 4h 2 4h 7 2h
A2780 2.9 ± 0.6 1.2 ± 0.5 2.0 ± 0.8 12.4 ± 2.7 4.3 ± 2.2 2.2 ± 1.0
ADDP 197 ± 82 63 ± 15 52 ± 13 239 ± 117 193 ± 43 625 ± 154
AG6000 17.1 ± 4.5 4.7 ± 0.9 4.5 ± 1.0 > 106 > 106 50500 ± 20200
H322 44.6 ± 9.2 15.3 ± 3.7 14.9 ± 2.7 708 ± 335 420 ± 201 120 ± 54
LL 7.5 ± 1.3 2.7 ± 0.7 2.9 ± 0.8 800 ± 100 27.3 ± 6.7 12.8 ± 4.4
The IC50 is defined as the concentration causing 50% growth inhibition in treated cells when compared to control cells. Values are means ± s.e.m. of at least
three separate experiments.
Table 2 Evaluation of the interaction between dFdC and CDDP in ovarian and NSCLC cell lines by median drug effect analysis
Cell line Exposure time (h) dFdC at approximate IC25 CDDP variable CDDP at approximate IC25 dFdC variable
Average CI ± SEM Average CI ± SEM
A2780 4 0.66 ± 0.17 0.45 ± 0.09
24 0.49 ± 0.16 0.40 ± 0.06
72 0.52 ± 0.10 0.41 ± 0.09
ADDP 4 0.16 ± 0.11 0.19 ± 0.05
24 0.19 ± 0.08 0.40 ± 0.02
72 0.28 ± 0.12 0.29 ± 0.08
H322 4 0.58 ± 0.31 1.01 ± 0.50
24 0.59 ± 0.08 0.68 ± 0.16
72 0.43 ± 0.16 0.74 ± 0.26
LL 4 1.31 ± 0.32 1.10 ± 0.32
24 0.46 ± 0.20 0.56 ± 0.20
72 0.43 ± 0.16 0.35 ± 0.13
Values represent the average CIs (non-mutually exclusive) of the fractions affected (FA) of 0.5, 0.75, 0.90 and 0.95 of the combination of dFdC and CDDP and
are means of at least three separate experiments. Cells were exposed to the combination in a non-constant ratio, either with CDDP at its approximate IC25, or
dFdC at its approximate IC25 combined with a range of the other drug with exposure times of 4-, 24- or 72-h exposure followed by 68-, 48- or 0-h drug-free
period. CI > 1 indicates antagonism, CI = 1 is additive and CI < 1 is synergism.(Van Moorsel et al, 1999). Doubling times of the cell lines were 21,
32, 37, 40 and 26 h respectively. A2780 and AG6000 cells were
cultured in Dulbecco’s medium with 5% heat-inactivated fetal calf
serum (FCS). ADDP cells were cultured in RPMI medium with 5%
heat-inactivated FCS. H322 and LL cells were cultured in RPMI
medium with 10% heat-inactivated FCS. A total of 250 ng ml–1
gentamicin was added to the media. All cell lines were growing
exponentially as monolayers during the course of all experiments.
Growth inhibition experiments
Growth inhibition experiments were performed in triplicate in 96-
well flat-bottom plates (Costar, Cambridge, MA, USA) essentially
as described previously (Peters et al, 1993a). Cells were seeded in
100-ml medium containing 5% FCS at different densities; 6000 per
well for A2780 cells, 12 000 per well for ADDP cells, 20 000 per
well for H322 cells and 5000 per well for LL cells. After 24 h,
100 ml of drug containing medium was added and cells were
cultured for another 72 h. After 4 and 24 h the cells were washed
and cultured in drug-free medium for 68 and 48 h respectively. Cells
were exposed to dFdC alone or to CDDP alone, or to a combination
of both drugs: one drug was added at a concentration causing about
25% growth inhibition, while the other drug was added at variable
concentrations. The used CDDP concentrations in A2780, ADDP,
H322 and LL cells for 4-h exposure were 6, 320, 88 and 2.7 mM
respectively; for 24-h exposure 1.2, 160, 30 and 1.5 mMrespectively;
and for 72-h exposure 1.2, 120, 30 and 1.5 mM respectively. The
used dFdC concentrations in A2780, ADDP, H322 and LL cells for
4-h exposure were 30, 320, 120 and 405 nM respectively; for 24-h
exposure 4.8, 320, 40 and 10 nM respectively; and for 72-h exposure
4.8, 1400, 20 and 10 nM respectively. The CDDP concentration
range for all cell lines was 10 nM to 0.5 mM, the dFdC concentration
range was 0.02 nM to 1 mM in A2780 cells, 0.2 nM to 2 mM in ADDP
and H322 cells and 5 nM to 10 mM in LL cells. Growth inhibitory
effects were evaluated with the standard sulphorhodamine B protein
(SRB) assay (Peters et al, 1993a). Growth of the cells was exponen-
tial during the whole incubation period. Relative growth was calcu-
lated as described previously (Monks et al, 1991; Peters et al, 1993a)
by: [(ODtreated– ODzero)/(ODcontrol– ODzero)] ´ 100%, when ODtreated
was ³ to ODzero. In case ODtreated was below ODzero, cell killing had
occurred. The optical density (OD) was read at 540 nm. The ODzero
depicts the cell number at the moment of drug addition, the ODcontrol
reflects the cell number of untreated wells and the ODtreated reflects
the cell number in treated wells at the day of the assay.
Mechanism of synergism between gemcitabine and cisplatin 983
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Figure 1 Representative growth inhibition curves of the cell lines A2780 (A), ADDP (B), H322 (C) and LL (D). Cells were exposed to dFdC alone (s) or in
combination with CDDP at an IC25 concentration (n) for 24 h. From the values of dFdC and CDDP alone the expected curve was calculated (l). After drug
exposure, all cell lines were cultured in fresh medium. Total culture time was 72 h. All growth inhibition assays were repeated at least three times and the
variation between experiments was always lower than 34%We evaluated possible synergism using the median drug effect
analysis method of Chou and Talalay (1983, 1994), processed by a
computer program developed by Chou and Hayball (1996) and
commercially available as CalcuSyn (Biosoft, Cambridge, UK).
Dm values (IC50 values) are calculated by the program by extrapo-
lation. For the separate drugs, the respective growth inhibition
parameters, expressed as fraction affected (FA) (e.g. a FA of 0.25
is a growth inhibition of 25%) were introduced. The CI (combina-
tion index) was calculated by the formula: CI = [(D)1/(Dx)1] +
[(D)2/(Dx)2] + [a(D)1(D)2/(Dx)1(Dx)2]. Where a = 1 for mutually
non-exclusive drugs; (D)1 and (D)2 are the doses of the separate
drugs and their combination; and (Dx)1 and (Dx)2 are the doses
resulting in a growth inhibition of x%. These doses are calculated
by the formula: D = Dm[FA/(1 — FA)]1/m, where Dm is the dose
required to produce a 50% growth inhibition, FA is the fraction
affected, and m is the slope of the median plot. Since CIs changed
with FA, the averaged CIs at IC50, IC75, IC90 and IC95 were used.
An average CI < 1 indicates synergism, > 1 indicates antagonism
and an average CI of 1 indicates additivity.
dFdCTP accumulation
The effect of CDDP on the accumulation of dFdCTP was studied
by exposing 2–4 ´ 105 cells, in 6-well plates in duplicate, to dFdC
(0.1 mM, 1 mM), or to dFdC and CDDP (20 mM, 200 mM) for 24 h.
As a control, non-exposed cells were cultured for the same period.
At the end of the incubation cells were washed in ice-cold PBS,
harvested by rapid trypsinization (1 min at room temperature) and
subsequently suspended in ice-cold culture medium with FCS,
immediately followed by chilling on ice and cell counting.
Nucleotides were extracted and analysed by HPLC as described
previously (Bergman et al, 1996; Ruiz van Haperen et al, 1994b).
Separation and quantification of the normal ribonucleotides and of
dFdCTP was achieved with a gradient HPLC system (Partisphere
SAX anion exchange column) connected to a photo-diode array
detector, regularly set at 254 and 280 nm as described previously
(Ruiz van Haperen et al, 1994b). Peaks were quantitated by a data
acquisition program.
[5-3H]-dFdC incorporation
Incorporation of 3H-dFdC into DNA and RNA was performed
essentially as described previously for measuring the incorporation
of 5-fluorouracil (5-FU) into RNA and DNA and 3H-deoxyuridine
into DNA (Peters et al, 1987; Van der Wilt et al, 1993) using 96-
well filter-bottom plates (Multiscreen® Filtration System, 0.22 mm
Hydrophilic Low Protein Binding Durapore® Membrane,
Millipore, Molsheim, France). Briefly, cells (about 150 000 per
well in 100 ml culturing medium) were plated and, after 24 h of
recovery, incubated with [5-3H]-dFdC (22 Ci mmol–1) (0.1 and
0.4 mM) alone, or in combination with CDDP (20 and 200 mM) for
24 h at 37°C. The incubation was terminated by the addition of
984 CJA van Moorsel et al
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Table 3 Effect of CDDP on the relative incorporation of dFdC into DNA and RNA of ovarian and lung cancer cells, corrected for inhibition of DNA and RNA
synthesis
Ratio:
dFdC incorporation into DNA
Ratio:
dFdC incorporation into RNA
TdR incorporation into DNA UR incorporation into RNA
Cell line dFdC alone dFdC + CDDP dFdC alone dFdC + CDDP
A2780 0.02 ± 0.01 (95%) 0.76 ± 0.16a (99%) 0.10 ± 0.02 (0%) 7.94 ± 0.88a (87%)
ADDP 0.05 ± 0.02 (92%) 0.03 ± 0.01 (80%) 0.12 ± 0.03 (0%) 0.64 ± 0.04 (0%)
H322 0.30 ± 0.03 (99%) 0.07 ± 0.02 (98%) 0.85 ± 0.09 (0%) 1.53 ± 0.40 (50%)
LL 0.00 ± 0.00 (76%) 0.01 ± 0.00 (71%) 0.38 ± 0.07 (0%) 0.55 ± 0.14 (0%)
Cells were exposed to 0.1 mM dFdC alone, or in combination with 20 mM CDDP, for 24 h. Incorporation of 3H-dFdC into DNA and RNA was divided by the
incorporation of TdR into DNA, and UR into RNA respectively. Values are means ± s.e.m. of three separate experiments (% DNA or RNA synthesis inhibition
caused by the drug(s)). aSignificantly different from dFdC alone (P < 0.01).
Table 4 Effects of dFdC and CDDP on DNA strand break (DSB) formation in ovarian and lung cancer cells after 24-h exposure to both compounds alone or in
combination
Cell line Concentration % DSB
dFdC (nM) CDDP (mM) dFdC CDDP dFdC + CDDP
A2780 1.5 0.75 –2.4 ± 5.8 10.7 ± 10.4 –3.4 ± 8.2
ADDP 1.5 0.75 38.9 ± 9.2 –4.2 ± 21.2 18.6 ± 24.0
AG6000 1.5 0.75 23.8 ± 1.6 –44.4 ± 30.5 6.8 ± 33.9
H322 100 5 22.3 ± 5.4 9.7 ± 9.7 –0.7 ± 2.3
LL 10 2 –1.4 ± 23.2 –14.0 ± 2.8 18.5 ± 2.9a
Values (in % decrease of amount of double-stranded DNA in untreated cells) are means ± s.e.m. of three separate experiments. aP = 0.04; measured DSB to
expected DSB (DSB of both drugs added together). Expected DSB formation: 8.3% in A2780, 34.7% in ADDP, –20.6% in AG6000, 32.0% in H322 and –15.4%
in LL cells. For comparison data of Bergman et al (1996) on the A2780 cell line are included. Exposure of cells to 10 mM VP-16 for 1 h was always included as
an internal control for the assay and gave the following extent of DSB formation: A2780: 25.7 ± 15.4, ADDP: 20.9 ± 10.8, AG6000: 15.0 ± 10.1, H322: 19.3 ± 7.4
and LL: 21.4 ± 5.5%. The actual levels of dsDNA in untreated cells at the end of the unwinding time were 86% in A2780, 96% in ADDP, 92% in AG6000, 87% in
H322 and 49% in LL cells. These values were subsequently set at 100% to calculate the relative values.trichloroaretic acid (TCA) as described previously by Van der Wilt
et al (1993). Incorporation into RNA was determined by adding 40
ml DNAase I (1 mg ml–1) and 60 ml PBS to one part of the wells and
an incubation for 30 min at 37°C. Incorporation into DNA was
determined by adding 20 ml RNAase A/T1 (500 U ml–1; DNAase-
free) and 80 ml PBS to the other part of the wells and incubation for
30 min at 37°C. The reaction was terminated by precipitation of
RNA and DNA, respectively, with TCA. Filters were washed with
water and ethanol and, subsequently, the filters were incubated with
NaOH to hydrolyse nucleic acids and counted. To determine the
amount of cells, duplicate cultures were exposed to similar concen-
trations of non-radiolabelled dFdC, harvested by rapid trypsiniza-
tion and counted. 3H-dFdC incorporation into DNA and RNA was
corrected for inhibition of DNA and RNA synthesis, as measured
by the incorporation of [2-14C]-thymidine (14C-TdR, 62.8 Ci mol–1,
2.5 mM) and [5- 3H]-uridine (3H-UR, 27 Ci mmol–1, 58.6 nM) added
to control cells and cells exposed for 24 h to dFdC and CDDP,
respectively, 2 h before the end of the incubation, using a similar
protocol as described before (Ruiz van Haperen et al, 1993). A ratio
was calculated between dFdC incorporation into DNA and RNA,
and TdR and UR incorporation into DNA and RNA, respectively,
as follows:
DNA: (fmol dFdC in DNA 10–6 cells)/(fmol TdR in DNA 10–6 cells)
RNA: (fmol dFdC in RNA 10–6 cells)/(fmol UR in RNA 10–6 cells)
FADU DNA-damage assay
The extent of DNA strand breaks (DSB) caused by dFdC and
dFdC in combination with CDDP were measured by the FADU
assay (Fluorometric Analysis of DNA Unwinding) as described
previously by Birnboim and Jevcak (1981) and slightly modified
(Bergman et al, 1996; Van der Wilt, 1997). This assay is based on
the principle that the rate of unwinding of DNA under alkaline
conditions depends on the presence of strand breaks; DNA with a
high amount of strand breaks will unwind faster under alkaline
conditions than DNA with no strand breaks. Double-stranded
DNA (dsDNA) can be detected by ethidium bromide (EtBr)
staining. Cells (about 5 ´ 106 cells) were incubated with CDDP
alone (ADDP and AG6000: 750 nM; H322: 5 mM; LL: 2.5 mM) or
in combination with dFdC (ADDP and AG6000: 1.5 nM; H322:
100 nM; LL: 10 nM) for 24 h at 37°C. Etoposide (VP-16) was used
as a positive control drug, and added at 50 mM to the cells 1 h
before harvesting. Untreated cells were used as controls. Cells
were harvested, kept on ice and directly used in the assay. For this
purpose the cells were suspended in 2 ml ice-cold 0.25 M
mesoinositol, 10 mM NaH2PO4, 1 mM magnesium chloride
(pH 7.2) and the suspension was divided equally among three sets
of tubes: T-, B- and P-tubes. All tubes were incubated with a buffer
containing a high concentration of urea to disrupt the chromatin.
T-tubes (total fluorescence) were then treated with glucose
containing buffer, to stabilize DNA so that unwinding could not
occur due to the alkaline environment. Subsequently, alkaline
buffer was added. B-tubes (background fluorescence) were
vortexed vigorously so that the dsDNA is sheared. All tubes were
incubated at 15°C so that the DNA could unwind and were then
put on ice. The glucose-containing buffer was then added to the P-
tubes (estimate of unwinding rate of the DNA caused by the drug)
and B-tubes. EtBr was added to all tubes and all tubes were
vortexed. The fluorescence was measured and the extent of DNA
strand breaks was calculated by: (P – B)/(T – B) ´ 100%.
Total cellular platinum accumulation
Cells (about 5 ´ 106 cells) were incubated with CDDP alone (20 and
200 mM), or in combination with dFdC (0.1 and 1 mM) for 24 h at
37°C. Cells were trypsinized, washed three times with ice-cold PBS,
harvested, counted and stored as pellets at –20°C. Before analysis,
500 ml benzethonium hydroxide (hyamine) per 1 ´ 106 cells was
added to the cell pellets. A total of 25 ml water was added to the
samples and standard curves were made by addition of 25 ml of stan-
dard CDDP-solutions (0.1–0.3 mM) in water to 1 ´ 106 non-treated
cells; all samples were vortexed and incubated overnight at 55°C;
thereafter 4.25 ml 0.2 M hydrochloric acid was added. Samples were
analysed on a Varian SpectrAA-10 atomic absorption spectrometer
(Varian UK, Walton-on-Thames, Surrey, UK) equipped with a
graphite furnace; data were formatted and archived on a personal
computer utilizing Varian Report Manager software. Samples were
dried at 95–110°C, ashing was performed at 1300°C and atomization
at 2600°C.
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Figure 2 Effect of CDDP on the accumulation of dFdCTP. For comparison,
previously published effects of the A2780 cell line are also included
(Bergman et al, 1996). Cells were exposed for 24 h to either 1 mM dFdC alone
(black bars) or in combination with 200 mM CDDP (white bars). Values are
means ± s.e.m. of three to five experiments. ND = not detectable, in A2780
because of cell death after combination of both compounds at these
concentrations. AG6000 did not accumulate dFdCTP (Ruiz van Haperen et
al, 1994)
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Figure 3 CTP pools in the A2780, ADDP, H322 and LL cell lines in control
cells (black bars), or after exposure of cells to 1 mM dFdC alone (white bars),
200 mM CDDP alone (crossed bars), or in combination (dense crossed bars)
for 24 h. Values are means ± s.e.m. of three to five experiments. ND = not
detectable, in A2780 because of cell death after combining both compounds
at these concentrations. *Significantly different from control levels, P < 0.05Platinum–DNA adduct determination
Cells were treated with CDDP (20 and 200 mM) alone or in combi-
nation with dFdC (0.1 and 1 mM) for 24 h at 37°C. After this time
period drugs were washed away and cells were cultured in drug-
free medium for another 3, 6 or 24 h. Cells were washed with PBS,
trypsinized and harvested on ice; the cell pellets (about 5 ´ 106
cells) were resuspended in 1.0 ml lysis-buffer (100 mM Tris, 5 mM
EDTA, 0.2% sodium dodecyl sulphate, 200 mM sodium chloride,
100 mg ml–1 proteinase K, pH 8.5) and incubated for 2 days at 37°C
with agitation. DNA was precipitated by mixing with 2-propanol
and dissolved in TE-buffer (10 mM Tris, 1 mM EDTA, pH 7.5).
DNA content was estimated by measuring optical density at 260
and 280 nm (protein content), all samples had an OD260/OD280 ratio
> 1.9 indicating uncontaminated DNA. A total of 0.1 volume
sodium chloride (1.65 M) was added to the dissolved DNA. A cali-
bration curve was made using different solutions of CDDP (0–1.5
mM) in TE-buffer containing 0.165 M sodium chloride. Pt content of
samples and standards was measured using AAS.
Statistical evaluation
Results were evaluated using the paired and unpaired Student’s
t-test. Relations between parameters were evaluated using the
Pearson’s correlation test.
RESULTS
Analysis of the interaction between dFdC and CDDP
The IC50s of dFdC and CDDP alone in the A2780, ADDP,
AG6000, H322 and LL cell lines are summarized in Table 1. Clear
differences were observed in the sensitivity for both drugs in these
cell lines: at all exposure times A2780 is the most sensitive cell
line for both compounds, followed by LL. The ADDP, AG6000
and H322 cell lines all are very resistant to dFdC (> 50-fold
compared to A2780). ADDP is the most resistant cell line to
CDDP (> 45-fold resistant), followed by H322 (> 7.5-fold resis-
tant) and AG6000 (> 3.5-fold resistant). Based on these sensitivity
data, combination experiments were designed in which cells were
exposed to the approximate IC25 of one drug and a concentration
range of the other drug. From the separate growth inhibition data,
expected curves could be calculated. Figure 1 shows representa-
tive growth inhibition curves for dFdC alone, the combination of
dFdC and CDDP, and the expected growth inhibition curves in the
A2780, ADDP, H322 and LL cell lines. It was remarkable that in
the A2780, ADDP and H322 cell lines the highest difference
between the expected and measured curve was observed at the
IC100 concentration of dFdC.
Synergism was analysed with the median drug effect analysis of
Chou and Talalay (1983, 1994), average CIs of the FA 0.5, 0.75,
0.90 and 0.95 are given in Table 2. At 4-h exposure of cells to the
approximate IC25 of dFdC in combination with CDDP synergism
was found in the A2780, ADDP and H322 cell lines. However,
slight antagonism was found in the LL cell line. At 24- and 72-h
exposures synergism was found in all cell lines. At 4-h exposure to
CDDP at the approximate IC25 and to dFdC in a concentration
range, the combination was synergistic in the two ovarian cancer
cell lines A2780 and ADDP. However, additivity was found in the
H322 cell line and moderate antagonism in the LL cell line. At 24-
and 72-h exposures synergism was found in all cell lines.
Effects on dFdCTP accumulation and normal
nucleotide pools
In order to determine a possible role of dFdCTP in the interaction
between dFdC and CDDP, we measured the accumulation of
dFdCTP after 24-h exposure to 1 mM dFdC alone, or in combina-
tion with 200 mM CDDP in the A2780, ADDP, H322 and LL cell
lines (Figure 2). dFdCTP accumulation after exposure to 1 mM
dFdC alone for 24 h did not show a clear relation with the sensi-
tivity of this panel of cell lines. A2780 cells, which are the most
sensitive to dFdC, clearly accumulated the highest amount of
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Figure 4 Effect of dFdC on the cellular accumulation of platinum in ovarian and lung cancer cell lines. Cells were exposed to either CDDP alone
(200 mM) (n) or in combination with dFdC (1 mM) (n n) for 24 h. Values are means ± s.e.m. of three to four experimentsdFdCTP. However, LL cells, which are the second most sensitive
to dFdC, accumulate the lowest amount of dFdCTP. CDDP did not
cause any significant changes in dFdCTP accumulation, even
though it tended to decrease dFdCTP accumulation 10, 25 and
50% in the ADDP, H322 and LL cell lines respectively. In A2780
cells, the combination of both compounds at these concentrations
was too toxic for reliable measurements of the dFdCTP accumula-
tion. Normal nucleotide pools were evaluated in the same analysis;
only CTP pools showed relevant changes and are shown in Figure
3. Incubation with 1 mM dFdC alone tended to increase CTP pools
2.6- and 3.7-fold in the H322 and LL cell lines (P = 0.09 and
P = 0.13) respectively, whereas no differences were found in the
A2780 and ADDP cell lines. CDDP alone also tended to increase
CTP pools in the H322 line 2.8-fold (P = 0.07). However, the
combination of both compounds resulted in a significant increase
of CTP pools in the ADDP, H322 and LL cells (1.9-, 6.7- and 3.4-
fold; P = 0.06, P < 0.01 and P = 0.03 respectively).
dFdC incorporation into DNA and RNA
To determine the possible contribution of dFdC incorporation into
DNA and RNA to the interaction between both compounds, incor-
poration of [5-3H]-dFdC into DNA and RNA was studied. Within
the panel of human cell lines the most sensitive cell line to dFdC,
A2780, incorporated threefold more dFdC into DNA (P = 0.02 and
P = 0.01 respectively) and fivefold more dFdC into RNA than the
more resistant cell lines ADDP and H322 respectively (P < 0.01
for both cell lines) (results not shown). However, the A2780 cell
line incorporated threefold less dFdC into DNA than the less-
sensitive murine LL cell line (P = 0.02). The amount of dFdC
incorporation into DNA did not show a clear relation with the
dFdCTP accumulation in these cell lines. The LL cell line accumu-
lated the lowest amount of dFdCTP; however, it incorporated the
highest amounts of dFdC into both DNA and RNA. Together this
possibly resulted in the rather sensitive phenotype.
The effects of CDDP on dFdC incorporation into DNA and RNA
were corrected for the incorporation of TdR and UR into DNA and
RNA as a parameter for DNA and RNA synthesis (Table 3). Using
this correction, CDDP increased dFdC incorporation into
both DNA and RNA of the A2780 cell line 33- and 79-fold
(P < 0.01) respectively, and did not influence the incorporation of
dFdC into DNA in the other cell lines. CDDP tended to increase the
dFdC incorporation into RNA in all cell lines. For the high drug
concentrations (both dFdC and CDDP), DNA and RNA synthesis
were completely inhibited and no reliable ratio could be calculated.
DSB formation
The extent of DSB formation after exposure to either CDDP or
dFdC alone, or to a combination of both compounds, was
measured to determine the possible contribution of this type of
DNA damage to the interaction between both compounds (Table
4). Expected values were calculated by addition of the amount of
DSB formed by each compound alone. In the wild-type ovarian
cancer cell line A2780, in the CDDP-resistant ADDP cells and in
the NSCLC H322 cells less DSB than expected tended to be
formed by the combination of dFdC and CDDP (differences:
11.7%, 16.1% and 32.7% respectively). However, in the dFdC-
resistant AG6000 cells, and in the murine LL cells, more DSB than
expected were formed (27.4% and 33.9% respectively; not signifi-
cant in AG6000 cells; P = 0.04 in LL cells).
Total cellular platinum accumulation
The amount of total Pt accumulating in cells after exposure of cells
to CDDP alone, or in combination with dFdC, was determined to
study whether dFdC would affect total cellular Pt accumulation.
Figure 4 shows the Pt accumulation in the ovarian cancer and
NSCLC cell lines after 24 h of incubation with either CDDP alone,
Mechanism of synergism between gemcitabine and cisplatin 987
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Figure 5 Pt–DNA adduct levels in DNA after 24-h exposure to CDDP alone
(solid bars) or CDDP and dFdC in combination (open bars), and 3-h
incubation in drug-free medium (hatched bars: CDDP alone; double hatched
bars: CDDP and dFdC in combination. (A) Results of 20 mM CDDP and
0.1 mM dFdC. (B) Results of 200 mM CDDP and 1 mM dFdC. This Figure
shows the mean data of at least three experiments ± s.e.m. *Significantly
different from CDDP alone, P < 0.05
Figure 6 Correlation between 3H-dFdC incorporation into DNA (data not
shown) and initial Pt–DNA adduct formation (Figure 5) in the A2780, ADDP,
H322 and LL cell lines. Pearson correlation r = 0.91. P-value (two-tailed) = 0.02or in combination with dFdC. In the A2780 cell line, exposure to
200 mM CDDP resulted in 60- and 17-fold higher Pt accumulation
than in the CDDP-resistant variants AG6000 and ADDP respec-
tively (P < 0.05). The NSCLC cell lines, H322 and LL, both accu-
mulated more Pt than the resistant ovarian cancer cell lines. Total
Pt accumulation in this panel apparently is not related to CDDP
sensitivity. A significant effect of dFdC on Pt accumulation was
only found in the ADDP cell line; dFdC caused a 2.1-fold increase
of Pt accumulation in this cell line (P = 0.04).
Pt–DNA adduct formation
Formation of Pt–DNA adducts is a critical event in the cytotoxi-
city of CDDP. Therefore, we studied whether dFdC might affect
the formation of Pt–DNA adducts and the Pt–DNA adduct reten-
tion (Figure 5A,B). The CDDP-resistant cell line ADDP clearly
formed 4.9-fold fewer Pt–DNA adducts compared to its sensitive
parental cell line A2780 (P = 0.02), which may be related to its
lower total cell Pt accumulation. This was in contrast to the
Pt–DNA adduct formation in the AG6000 cell line, which was
similar to that in the A2780 cell line, although Pt accumulation
in the AG6000 cells was much lower than in A2780 cells. The
Pt–DNA adduct formation in the LL lung cancer cell line was
fourfold higher than that in the H322 cells (P < 0.01), which was in
line with the higher Pt accumulation in these cells. dFdC increased
the Pt–DNA adduct formation compared to CDDP alone in all cell
lines except in H322 and ADDP cells at the low concentrations.
However, in the ADDP cell line, adduct levels were at the
detection limit of the atomic absorption spectroscopy. At the high
CDDP concentration, dFdC increased the Pt–DNA adduct forma-
tion in ADDP cells almost to the level found in A2780 cells treated
with CDDP alone. The level of Pt–DNA adduct formation corre-
lated with the incorporation of dFdC into DNA after 24 h exposure
to dFdC alone (Figure 6).
The retention of the Pt–DNA adducts formed after exposure to
200 mM CDDP was increased similarly at 3 (Figure 5B), 6 and
24 h (data not shown) by co-exposure to 1 mM dFdC in the LL cell
line (1.4-, 1.3- and 1.3-fold; P < 0.01, P < 0.18 and P < 0.19 respec-
tively). However, in the dFdC-resistant AG6000 cell line, the 6-
and 24-h Pt–DNA adduct levels in cells after treatment with the
combination of dFdC and CDDP were 85% of the levels in cells
treated with CDDP alone (P = 0.10 and P < 0.01 respectively) (data
not shown). In all other cell lines no effect of dFdC on the 3-, 6- and
24-h retention of Pt–DNA was found. However, in most cell lines
the level of Pt–DNA adducts 24 h after exposure to CDDP did not
decrease significantly compared to the 3- and 6-h levels. Only in
the AG6000 cells did Pt–DNA adduct levels decrease to about 50%
of the initial levels (data not shown). It is possible that cells lacked
an intact enzyme system due to these high concentrations, and thus
were inhibited in their ability to repair DNA damage.
Therefore, we focused on the combination of 20 mM CDDP and
0.1 mM dFdC (Figure 5A). dFdC significantly increased the reten-
tion of Pt–DNA adducts in the A2780 cell line (P < 0.05). However,
this effect did not last longer than 3 h and seemed to be due to the
initial increase in Pt–DNA adduct levels rather than to DNA repair
inhibition. In the LL cell line, dFdC caused a twofold decrease in
Pt–DNA adducts after exposure to the low concentration of CDDP
(P= 0.02). However, note that the Pt–DNA adduct levels after expo-
sure to 20 mM CDDP were just above the detection level. In the
AG6000, ADDP and H322 cell lines, dFdC did not seem to affect
Pt–DNA adduct retention 3, 6 and 24 h after exposure.
When evaluated as total exposure to Pt–DNA adducts, in all cell
lines except for the H322, the areas under the curve for Pt–DNA
adduct levels tended to be higher for the dFdC–CDDP combina-
tion (a 1.5-, 2.2-, 1.4- and 1.8-fold increase in the A2780, ADDP,
AG6000 and LL cell lines respectively (data not shown).
DISCUSSION
In this study we showed synergism between dFdC and CDDP in
several ovarian cancer and NSCLC cell lines. The most
pronounced effects were found in the CDDP-resistant cell lines
when CDDP was used around its IC25 and dFdC in a concentration
range. The mechanism of this synergistic interaction is most likely
due to an increased Pt–DNA adduct formation, possibly related to
the incorporation of dFdC into DNA.
Using a different approach of drug exposure than in previous
studies, synergism was found in a panel of five different cell lines. It
was remarkable that in some cell lines the best effect was observed at
the IC100 concentration of dFdC, indicating that the combination can
exert significant anti-tumour activity by killing cells. The concentra-
tions used in this study to achieve synergism are in agreement with
levels of both drugs that can be reached in patients (Vermorken et al,
1984; Abbruzzese et al, 1991; Peters et al, 1993a; Freeman et al,
1995; Van der Uijgh, 1991). Combination of both compounds has led
to increased response rates in various cancer types, such as ovarian
cancer and NSCLC, in which response rates up to 71% were
observed (Steward et al, 1996; Abratt et al, 1997; Crino et al, 1997;
Van Moorsel et al, 1997; Krakowski et al, 1998; Nogue et al, 1998).
The present studies were performed to elucidate the mechanism of
the interaction between dFdC and CDDP; therefore, various parame-
ters related to the mechanism of action of both compounds were
investigated. dFdCTP accumulation was related to sensitivity to
dFdC of all cell lines tested in this study and in previous studies (Ruiz
van Haperen et al, 1994b; Bergman et al, 1996) (except for the
murine LL cells). CDDP did not cause any significant changes in
dFdCTP accumulation, but tended to decrease the dFdCTP accumu-
lation in the ADDP, H322 and LL cell lines. This phenomenon might
be the result of the highly toxic combination of both compounds.
However, since this decrease in dFdCTP accumulation was seen in
dFdC- and CDDP-sensitive, as well as -resistant, cell lines in this
study and in a previous study (Bergman et al, 1996), a more likely
possibility is the rise in CTP and UTP pools, caused by both CDDP
and dFdC. Both CTP and UTP can moderately inhibit the activity of
dCK in competition with ATP (Ruiz van Haperen et al, 1996), there-
fore a rise in CTP and UTP might decrease the accumulation of
dFdCTP. However, CDDP might also inhibit dFdC uptake of cells
directly, which was already shown for 2¢-deoxy-5-azacytidine
(DAC), another deoxycytidine analogue (Ellerhorst et al, 1993).
In this study, no relation was found between dFdC incorporation
into DNA and sensitivity to dFdC. The higher dFdC incorporation
into DNA in LL cells than in the more dFdC-sensitive A2780 cell
line might be due to the higher inhibition of DNA synthesis in
A2780 cells, since this difference disappears after correction of the
incorporation of dFdC for the inhibition of DNA synthesis. In the
A2780 cell line, CDDP increased the incorporation of dFdC into
DNA, possibly due to the inhibition of RR by both CDDP and
dFdC (Heinemann et al, 1988; Chiu et al, 1992). Further research
is warranted to study the mechanism responsible for the increase
in dFdC incorporation into RNA and DNA by CDDP.
To study the possible interaction of both compounds with
respect to DNA damage, we determined the effect of both drugs on
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any damage were the ovarian cancer cell line A2780 and the
murine cell line LL, whereas CDDP caused DNA damage only in
A2780 and H322 cells. CDDP even seemed to have a protective
effect on DSB (values < 0%) in AG6000 and LL cells, which
might be caused by the interstrand cross-links formed by this
compound. In a previous study by Bergman et al (1996) it was
postulated that dFdC incorporation into DNA could result in inhi-
bition of the repair of Pt–DNA adducts, causing apparent stabiliza-
tion of DNA. In the present study, this effect was indeed found
in the A2780, ADDP and H322 cells, where a trend of less
DSB formation than expected was found. However, in dFdC-resis-
tant AG6000 cells more DSB than expected were formed, indi-
cating that dFdC is necessary for the increase in DNA
stabilization. An increase in DSB were also found in the murine
cell line LL. Whether this phenomenon in the LL cell line is of
much importance for the human situation remains to be seen.
However, the above mechanisms apparently are not the only
explanation for the synergistic interaction between both
compounds in these cell lines.
dFdC hardly affected cellular Pt accumulation. The only excep-
tion was the ADDP cell line, in which dFdC clearly increased the
Pt accumulation. In the cell CDDP binds to both DNA and protein,
but to a much larger extent to protein (99%); thus the increases in
Pt accumulation in ADDP cells (overall 30%) cannot be explained
by the increase in Pt–DNA adduct formation. Therefore, an effect
of dFdC on the binding of CDDP to intracellular proteins cannot
be excluded.
The increase in Pt–DNA adduct formation could be the result
of several effects of dFdC at the DNA level. Studies on the
mechanism of interaction between DAC and CDDP revealed an
increase of Pt–DNA binding on DAC substituted plasmid DNA
(Abbruzzese and Frost, 1992), which was not hypomethylation
dependent. Similarly, in our study there was a correlation between
the incorporation of dFdC into DNA and the initial Pt–DNA
adduct formation. The incorporation of dFdC into DNA could lead
to structural changes favouring the binding of Pt to the guanine
nucleotide opposite to the cytosine nucleotide and thus be of major
importance in the synergistic interaction of both compounds.
Since the retention of DNA platination was not increased in the
cell lines studied, dFdC did not seem to affect the overall DNA
repair of Pt–DNA adducts in this setting. However, since the initial
rapid repair of Pt–DNA adducts already starts a few hours after the
adduct formation, this effect could in this study have been masked
by the prolonged exposure period we used to be in accordance
with the growth inhibition experiments.
Strikingly, the largest increase in initial Pt–DNA adduct forma-
tion by dFdC was found in the CDDP-resistant ADDP cell line,
although this cell line did not show a significant increase in DNA
stabilization after exposure to CDDP combined with dFdC. dFdC
might favour the formation of intra- instead of interstrand Pt cross-
links in this cell line. No increase in formation and retention of
Pt–DNA adducts was found in the H322 cell line. Since this cell
line had the lowest level of dFdC incorporation into DNA, it might
be postulated that a certain threshold dFdC incorporation is needed
in a cell to induce the increased Pt–DNA adduct formation.
This study shows that the combination of dFdC and CDDP can
be synergistic in various cancer cell lines with a different histo-
logic origin. The mechanism of this synergy is most likely an
increase in the formation of Pt–DNA adducts, possibly related to
the incorporation of dFdC.
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